AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Saturday 24 October 2026
News from the 24 hours to Saturday morning, 24 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mainly positive, with new approvals for Ultomiris in the US and Enhertu in China, plus a $1.46 billion AI deal. Analysts also stayed supportive ahead of upcoming results, with Jefferies keeping its price target.
What drove it
- drug approvals
- AI deal
- analyst support ahead of results
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 18 Oct | +5.7 | 6 |
| Mon 19 Oct | +4.0 | 3 |
| Tue 20 Oct | +5.5 | 24 |
| Wed 21 Oct | +8.7 | 38 |
| Thu 22 Oct | +8.3 | 28 |
| Fri 23 Oct | +8.3 | 32 |
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
7 stories · 8 headlines · strongest first
Pharma and healthcare on 24 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| FDA gives Ultomiris accelerated approval for IgA nephropathy +9.32 headlines today · 18 in all, since 22 October · Ultomiris received US FDA approval for a rare kidney disease, with approvals cited as lifting the shares. | ||
| +10.0 | Shares rise after approvals for Ultomiris and Zegfrovy. | |
| +10.0 | FDA clears Ultomiris for a rare kidney condition in the US. | |
| China conditionally approves Enhertu for an additional indication +10.01 headline today · AstraZeneca and Daiichi Sankyo's Enhertu received conditional approval in China. | ||
| +10.0 | Enhertu wins conditional China approval for new indication. | |
| AstraZeneca signs $1.46bn AI deal +6.31 headline today · 4 in all, since 20 October · AstraZeneca agreed an AI deal worth USD 1.46 billion. | ||
| +9.2 | Signs $1.46bn AI deal ahead of results. | |
| Seeking Alpha view: AstraZeneca is undervalued before its third-quarter results +8.31 headline today · Seeking Alpha piece calls AstraZeneca undervalued ahead of Q3. | ||
| +8.3 | Analyst view calls shares undervalued ahead of Q3 results. | |
| Jefferies keeps AstraZeneca target at 17,500p +7.51 headline today · Jefferies keeps its target. | ||
| +7.5 | Jefferies keeps high price target on shares. | |
| Breztri AI-created llama ads +3.31 headline today · MediaPost covers Breztri's AI-created ad campaign. | ||
| +3.3 | Breztri is an AstraZeneca brand; ad campaign gets positive coverage. | |
| FTSE 100 earnings week ahead includes AstraZeneca 0.01 headline today · Week-ahead preview lists AstraZeneca among busy earnings. | ||
| 0.0 | Earnings preview naming AstraZeneca among several; factual. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.